Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2016-11-15
Lead Sponsor
Sanofi
Target Recruit Count
3222
Registration Number
NCT00021255
Locations
🇻🇪

Sanofi-Aventis Administrative Office, Caracas, Venezuela

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2014-05-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
84
Registration Number
NCT00004888
Locations
🇺🇸

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

First Posted Date
2003-01-27
Last Posted Date
2014-06-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00049283
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-06-19
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00045227
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

First Posted Date
2003-01-27
Last Posted Date
2016-07-12
Lead Sponsor
Alliance for Clinical Trials in Oncology
Registration Number
NCT00041171

Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2003-01-27
Last Posted Date
2014-05-06
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
10
Registration Number
NCT00039520
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

First Posted Date
2003-01-27
Last Posted Date
2017-04-28
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
57
Registration Number
NCT00017563
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

🇺🇸

Portland VA Medical Center, Portland, Oregon, United States

Docetaxel in Treating Patients With Solid Tumors

First Posted Date
2003-01-27
Last Posted Date
2016-07-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
109
Registration Number
NCT00003565
Locations
🇺🇸

Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 71 locations

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

First Posted Date
2003-01-27
Last Posted Date
2016-07-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
259
Registration Number
NCT00012220
Locations
🇺🇸

Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

🇺🇸

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

🇺🇸

Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States

and more 73 locations

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Phase 1
Completed
Conditions
Cancer
First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
26
Registration Number
NCT00049296
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy